In major histocompatibility complex (MHC)-matched allogeneic hematopoietic stem cell transplantation (HSCT), donor responses are directed against multiple host minor histocompatibility antigens (mHAgs), producing graft-versus-host disease (GVHD) and graft-versustumor (GVT) effects. We studied MHC-matched, mHAgmismatched C3H.SW4C57BL/6 HSCT in which three mHAg are molecularly defined (B6dom1, H3, H13) to determine if there is a hierarchy of immunodominance among the mHAgs and to learn the contribution of each to GVHD. We found that B6dom1 was the immunodominant mHAg. B6dom1 did not block responses to the subdominant mHAgs H3 and H13. The mechanism of immunodominance was not mHAg avidity or affinity for class I. B6dom1 elicited a broader variety of Vb clonotypes than either H3 or H13. Severe GVHD could occur in the absence of a strong B6dom1 response. Alloreactivity to isolated B6dom1, H3 or H13 differences did not produce severe GVHD. We concluded that immunodominance is explained by both mHAg density on host cells and the repertoire of donor T cells capable of responding to the mHAgs. Clinically significant GVHD requires donor responses to multiple mHAgs. Modulation of responses to a single immunodominant mHAg is insufficient for the prevention of GVHD, while immunotherapies directed against isolated mHAgs may not provoke severe GVHD.
ibility antigen
Major histocompatibility complex (MHC)-matched allogeneic hematopoietic stem cell transplantation (HSCT) is commonly performed for the treatment of leukemia and a variety of hemoglobinopathies, immune deficiencies and inborn errors of metabolism. Despite genotypic identity of MHC alleles between donors and recipients in such transplants, clinically significant donor immune responses are directed against allogeneic host minor histocompatibility antigens, producing undesirable graft-versus-host disease (GVHD) and/or desirable graft-versus-tumor (GVT) effects. In the naturally outbred human population only a handful of minor histocompatibility antigens have been characterized. In contrast, in some murine systems minor histocompatibilty antigens (mHAgs) are more thoroughly characterized. A number of laboratories employ an HSCT model using H-2 b C3H.SW donors and H-2 b -matched C57BL/6 recipients for the study of GVHD and GVT effects. C3H.SW are H-2 b congenic mice derived from an 11-generation backcross of C3H (H-2 k ) against a noninbred H-2 b donor strain. 1 Known differences between C57BL/6 and C3H.SW include the H-1, H-3, H-7, H-8, H-9 and H-13 loci as functionally characterized by skin or tumor transplantation studies. 2 Recently, three of these functionally defined mHAgs have been molecularly characterized: B6dom1, 3 H3 4 and H13. 5 B6dom1 is a peptide epitope of the H-7 minor histocompatibility locus gene product, while H3 and H13 peptide epitopes are derived from polymorphic genes associated with the H3 and H13 loci. All three peptides are ubiquitously expressed in the tissues of C57BL/6 mice.
In some complex immunological responses such as antiviral responses or GVHD some antigens are immunodominant, that is, despite the presence of multiple potentially antigenic epitopes, the immune response is focused on the immunodominant epitope, while responses to others are weak or absent. 6 In the C3H.SW 4 C57BL/6 model, studies in other laboratories have demonstrated that B6dom1 can suppress the elicitation of a C3H.SW immune response to the male-specific HY mHAg on male C57BL/6 cells. 7, 8 Based on this phenomenon, B6dom1 has been described as an immunodominant antigen.
In other recent work both from our laboratory and from others, an allogeneic donor strain anti-B6dom1 immune has been shown to be associated with both GVHD and allogeneic GVT effects. [9] [10] [11] There is widespread interest in finding methods to manipulate HSCT that will increase GVT effects while minimizing GVHD. To reach this goal, it will be necessary to understand the ensemble of donor responses to multiple donor mHAg. Therefore, we conducted experiments to determine if there is a hierarchy of immunodominance among the molecular defined mHAgs and to determine the relative contribution of each to GVHD.
Materials and methods

Animals and cell lines
Female C57BL/6 ('B6', H2 b ) mice were purchased from the National Cancer Institute (Frederick, MD, USA). C3H.SW/Sn ('SW', H2 b ) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). From the day of irradiation until 2 weeks after bone marrow transplantation (BMT), the mice were provided with acidified water (pH 2.5) supplemented with 2 g/l neomycin sulfate (Sigma, St Louis, MO, USA). The T2D b cell line (kindly provided by P Cresswell, Yale University) was created by the transfection of human T2 cells with H2-D b gene; 12 205 is a C57BL/ 6 fibrosarcoma cell line. 13 Con A lymphoblasts (CAB) are normal splenocytes cultured for 2 days in the presence of conconavalin A 2 mg/ml. The cells were grown in RPMI-1640 supplemented with 5% heat-inactivated fetal bovine serum (FBS) (Biowhittaker, Walkersville, MD, USA) and 2 mmol/l l-glutamine.
Peptides
Peptides were synthesized using standard FMOC chemistry in a solid-phase synthesizer (Symphony, Protein Technologies Inc., Rainin Instrument Co., Woburn, MA, USA). The crude peptide material was purified by HPLC and the fractions whose purity was 497%, as measured by analytical HPLC, were combined and lyophilized. Co source 1 day prior to transplantation (D-1). Donor (SW) bone marrow was isolated by flushing femurs and tibias with sterile tissue culture medium. Spleen cells were prepared as single-cell suspensions by maceration using glass slides followed by erythrocyte lysis. On the day of transplantation (D-0), recipient C57BL/6 mice received 4 Â 10 6 bone marrow and 10 Â 10 6 SW spleen cells i.v. in a total volume of 0.2 ml of HBSS.
Immunization protocol
In some experiments, female donor SW mice were immunized two or three times weekly as specified in the legends with either 20 Â 10 6 male or female C57BL/6 spleen cells. As controls for HY responses, female SW mice were immunized twice with similar number of male SW cells. At 2 weeks after the last immunization, the spleens were isolated and stimulated in vitro either with male C57BL/6, male SW spleen cells or peptide-labeled antigen-presenting cells (as specified in the legends), and assayed for CTL responses. Peptide-specific immunizations were carried out in the following way. Female SW mice were injected s.c. three times at weekly intervals with 5 Â 10 6 50-Gy irradiated T2D b cells labeled with saturating concentrations of each peptide. B6dom1 tolerance was induced by i.v. infusion of synthetic B6dom1 peptide prior to immunization with whole 205 cells. C3H.SW donor mice received i.v. infusions of 300 mg of peptide on days À26, À23, À20, À17, À14 and À7. They were alloimmunized with 5 Â 10 6 irradiated 205 tumor cells s.c. on days À14 and À7. Donor cells were harvested on day 0. A portion of the cells were tested for anti-B6dom1 cytolytic activity and the remainder used for transplant into irradiated C57BL/6 mice.
Cytotoxicity assays
Spleen cells were cultured in six-well plates at 1 Â 10 6 cells/ ml in complete media (R10S) consisting of 10% FBS (Summit Biotech, Collins, CO, USA), 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mm l-glutamine, 100 mm sodium pyruvate, 0.1 mm nonessential amino acids and 50 mm 2-mercaptoethanol. As stimulators, 0.125 Â 10 6 naive SW spleen cells were pulsed with 35 mg of either B6dom1, H3, H13 or NP-peptides in a total volume of 10 ml. Irradiated stimulators were washed in R10S and resuspended at a final number of 1.25 Â 10 4 cells/ml and added to effectors. After 5 days in culture, the cells were harvested and plated in triplicate with 5 Â 10 3 51
Cr-labeled target per well at effector-to-target (E : T) ratios ranging from 200 : 1 to 12.5 : 1. Target cells were labeled by combining 5 Â 10 6 cells in 60 ml of R10S and 40 mg of the appropriate peptide 1 mg/ml and 0.1 ml (100 mCi) sterile Na 2 51 CrO 4 (Amersham, Arlington Heights, IL, USA) for 1 h at 371C. Labeled targets were washed three times before plating with effectors in a total volume of 0.2 ml/well in 96-well, round-bottomed plates. The cultures were incubated at 371C for 4 h and 0.1 ml of the supernatant was counted in a gamma counter (Wallac, San Francisco, CA, USA). The percentage of lysis was calculated as 100 [(experimental cpmÀspontaneous cpm)/(maximum cpmÀspontaneous cpm)].
ELISPOT assay
ELISPOT plates (Millipore) were prepared by coating wells with 10 mg/ml IFN-g capture antibody (Pharmingen). Effector splenocytes (1 Â 10 6 cells/well) were stimulated with either peptide (3 mg/well) or irradiated whole spleen at (0.5 Â 10 6 cells/well) 371C for 48 h. The plates were then washed four times in PBS and PBS-0.2% Tween (PBS-T) and incubated with detection antibody at 1 mg/ml for 2 h at room temperature. Following four washes in PBS-T, HRPconjugated streptavidin (Endogen) was added to the wells at 1 : 2000 dilution in PBS-T for 1 h at room temperature. The plates were washed four times in PBS-T and substrate 3-amino-9ethylcarbazole (Sigma) was added to the plates. Color development was monitored visually and the spots were counted using an inverted microscope (Leica).
Pretreatment in vivo with B6dom-1 peptide
To blunt B6dom1-specific T-cell responses in vivo, naive SW animals were intravenously injected with 300 mg of B6dom-1 peptide every 3 days (days 0, 3, 6 and 9) for a total of four times. On day 10, the animals were immunized with 5 Â 10 6 B6 spleen cells. A single additional i.v. injection of B6dom-1 peptide was given the day before the second immunization (day 16) with B6 spleen cells. A week after the last immunization, the splenocytes and bone marrow were harvested for BMT as described above.
Peptide/MHC affinity and stability measurements Peptide affinity and stabilities were measured using D b -transfected T2 cells (a TAP-deficient human lymphoidderived cell line 12 ). Cells were incubated overnight at 261C to enhance the expression of class I molecules. 6 Peptidebinding measurements were carried out by flow cytometry for increased expression of D b molecules using FITClabeled anti-H2-D b MHC class I mAbs (Caltag). T2 cells were incubated with a decreasing concentration of each peptide and subsequently incubated at 371C for 2 h to unfold the D b molecules not stabilized by the peptide. Peptide avidities were measured as follows: T2D b molecules were preincubated with the saturating concentrations of each peptide in the presence of brefeldin A (Sigma) at 261C for 1 h followed by incubation at 371C. At various time points (0, 2, 6 and 24 h) thereafter cells were analyzed by flow cytometry for the relative quantity of surface class I molecules.
Flow cytometry of Vb clonotypes
Spleen cells from C3H.SW mice immunized twice with C57BL/6 spleen cells were stimulated in vitro with either allogeneic C57BL/6 spleen cells or syngeneic C3H.SW spleen cells pulsed with the peptides B6dom1, H3 or H13. In these short-term cultures, antigen stimulations were performed on days 0, 8, 15 and 22; rIL-2 at 20 U/ml was added on days 8, 15 and 22. On day 28, cells were analyzed by flow cytometry using a screening panel of FITC-labeled mouse anti-Vb TCR antibodies (Pharmingen) and PE-labeled anti-CD8. Immune cells were pooled from three donors prior to in vitro stimulation. Freshly isolated normal C3H.SW spleen cells were also assessed as a control. Data are presented as percent Vb clonotype of total CD8 + cells.
GVHD evaluation
Mice were examined daily for survival. Weights were measured weekly. Observations of hair loss, hunched posture and inflammation of skin and periorbital tissues were recorded weekly. At the conclusion of experiments or when animals were moribund, liver and intestines were fixed in 10% formalin and paraffin embedded. Sections were stained with hematoxylin and eosin and examined for infiltrates characteristic of GVHD. 16 Histopathologic evaluation of slides was performed by a scorer blinded to the identity of the sections.
Results
The mHAg B6dom1 is immunodominant relative to the H3 and H13 mHAgs
In the light of the previously described immunodominance of B6dom1 over HY, 7, 8 we hypothesized that B6dom1 would exert similar immunodominance over the mHAgs H3 and H13, that is, the presence of the B6dom1 antigen would effectively block donor immune responses to H3 and H13. To test this, we immunized female C3H.SW mice with C57BL/6 spleen cells (which express B6dom1, H3, H13 and HY) and measured peptide-specific cytolytic T-cell activity following in vitro restimulation of the female C3H.SW splenocytes with male C57BL/6 splenocytes. A strong cytolytic response to B6dom1 was measured, but cytolytic responses were undetectable or weak against H3, H13 and HY mHAg (Figure 1a ), providing evidence supporting the hypothesis. Work by others exploring the immunodominance of B6dom1 over HY has suggested that in part the phenomenon is explained by B6dom1 more effectively competing for MHC class I occupancy than the HY peptide. 8 If this were also true in the B6dom1, H3 and H13 mHAg hierarchy, we would hypothesize that responses to H3 and H13 in vivo to be more easily detected in vitro if alloimmunized splenocytes could be specifically restimulated by H3 or H13 without competition by B6dom1 on the APC. Additional experiments were conducted in female C3H.SW mice immunized against female C57BL/6 mice to eliminate the potentially confounding variable of immunodominance against HY. Spleen cells from twice-C57BL/6-immunized animals were restimulated with C3H.SW APCs exogenously loaded with B6dom1, H3 or H13 peptides in vitro as opposed to whole C57BL/6 cells that contain the entire ensemble of minor antigens. As shown in Figure 2a , with selective mHAg restimulation significant anti-H3 and anti-H13 CTL responses were more readily detectable (compared to Figure 1a in which in vitro restimulation was performed with whole C57BL/6 cells). However, the response to B6dom1 was still quantitatively greater than the responses to H3 and H13. Similar results were seen in interferon-g ELISPOT assays (Figure 2b ). These assays also demonstrated the existence of H3-and H13-specific effector T cells in alloimmunized mice, again at much lower frequencies than those specific for B6dom1.
The ELISPOT assay suggested that H3-and H13-specific CTLs are present in vivo, but at a lower precursor frequency than B6dom1-specific CTLs. We hypothesized that an additional priming in vivo should induce further clonal expansion in response to H3 and H13 and produce a more robust cytolytic response. Following an additional third immunization and subsequent restimulation with male C57BL/6 cells, female SW mice were still unable to respond to HY (Figure 3a) , confirming the prior observation of B6dom1 immunodominance over HY. In contrast, significant killing of H3 targets was observed after three immunizations and H13 targets were killed at low but detectable levels (Figure 3a) . ELISPOT analysis confirmed the CTL data showing that B6-immune splenocytes secreted IFN-g when stimulated with B6dom1, H3 or H13 in vitro but not against HY (Figure 3b ). One factor that may contribute to the relative magnitude of the T-cell responses is the magnitude of help present for effector T-cell responses to antigen. To determine whether the nondominant mHAg responses would be enhanced by additional help, exogenous IL-2 was included in the ELISPOT assay. Again no HY-specific IFN-g secretion was observed despite the presence of exogenous IL-2, while the number of IFN-g secreting T cells specific for B6dom1, H3 and H13 were enhanced in vitro (Figure 3c ).
In contrast to the immunodominance relation between B6dom1 and HY, the anti-B6dom1 response did not completely block responses to H3 and H13. We hypothesized that this preference towards B6dom1 is due to suboptimal expansion in vivo of anti-H3-and anti-H13-specific CTLs. If this is true, we should be able to reverse peptide/MHC/TCR competition when these minor peptides are presented on separate antigen-presenting cells. To test this hypothesis animals were immunized with T2-D b cells pulsed with a single mHAg (B6dom1, H3 or H13). Figure 4 shows the IFN-g ELISPOT results after the first and third immunizations. Following the first immunization with single alloantigens, the number of IFNg-secreting cells responding to B6dom1, H3 and H13 were very similar for the mHAg-immune animals. However, after three immunizations, B6dom1-specific IFN-g responses quantitatively dominated the immune response as compared with H3 and H13 responses (Figure 4) . A cohort of the triply immunized animals was also assessed for cytotoxic T-cell function. As expected with immunization with mHAgs, no specific lysis was observed 7 days after the first immunization (data not shown). However, similar to prior experiments CTL Following in vitro restimulation with irradiated male C3H.SW cells, CTL activity against HY peptide loaded SW Con A blasts was measured. Lysis of Con A blasts not loaded with HY peptide was o10%.
Immunodominance among minor antigens in allo-HSCT S Mori et al activity was observed following the third immunization. The assay showed superior and specific lysis of B6dom1-labeled targets by B6dom1-specific CTLs (70% lysis at E : T 100). Anti-H3 CTL activity was approximately one-third of the magnitude of B6dom1 (25% lysis at E : T 100) and anti-H13 approximately one-seventh (10% lysis at E : T 100). Thus in both ELISPOT and CTL assays, the immunodominance of B6dom1 was preserved even when there was no competition in vivo or in vitro between the mHAgs for presentation on class I molecules.
The immunodominance of B6dom1 over H3 and H13 cannot be explained by peptide/MHC affinity or avidity
Immunogenicity of an antigen is partly dependent upon (i) its affinity for the MHC molecule (association rate) and (ii) the stability of the peptide-MHC complex following binding (dissociation rate). 6, 7 In other systems, immunodominance is related to the ability of immunodominant epitopes to compete with other antigens for MHC binding (affinity) and subsequent dissociation. 6, 17, 18 We hypothesized that the immunodominance of B6dom1 over H3 and H13 was related to the relative abilities of the peptides to associate with and dissociate from the MHC class I molecule. For comparative purposes we used two controls: , a wellcharacterized immunogenic peptide. 19, 20 The measurements of peptide kinetic binding were performed using flow cytometrical analysis of D b -transfected T2 cells (a TAPdeficient human lymphoid-derived cell line). In these cell lines, D b molecules are unstable and dissociate rapidly in the absence of a stabilizing exogenous peptide complexed with MHC class I molecules. 8 As can be seen from Figure 5 , all peptides were able to bind to the D b molecules on the surface of T2-D b cells. Despite their greater immunogenicity, B6dom1 and the influenza virus nucleoprotein epitope (NP 366 ) displayed 1.5 to 2-fold lower affinity for the MHC class I molecules compared to H3 and H13 at the lowest concentration of the peptides (1 mm). Indeed, as much as a 100-fold higher peptide concentration of B6dom1 could not confer similar degree of class I stabilization imparted by the lowest concentration H3 and H13 peptides tested ( Figure 5 ). HY displayed a higher affinity for D b molecule than B6dom1 suggesting no correlation between immunogenicity and peptide affinity in this model.
In other systems in which initial peptide affinity does not account for immunogenicity, high avidity or high stability of peptide-class I molecule complexes (ie, low dissociation rate) has been observed with immunodominant antigens. 6 To measure peptide dissociation, T2-D b cells were incubated with saturating concentrations of each peptide and the amount of residual D b molecules were monitored over a 24 h period. As shown in Figure 6 , the dissociation rates of all the mHAg peptide-class I complexes were similar leading to rejection of the hypothesis that peptide-class I avidity accounts for immunodominance in this system.
Comparison of Vb clonotypes responding to mHAgs
The size and number of clonal lymphocyte populations that can respond to an antigen influences the magnitude of an immune response. One surrogate measure of clonal diversity is the spectrum of Vb clonotypes elicited by an antigen. We hypothesized that the greater response to B6dom1 may be associated with a greater diversity of clonotypes. Flow cytometric analysis of CD8 + Vb clonotypes was performed on short-term lines of C3H.SW spleen cells responsive in vitro to intact C57BL/6 cells or to isolated B6dom1, H3 or H13 peptides (Figure 7) . The Vb profile of immune cells stimulated by intact C57BL/6 cells was very similar to the profile of naive C3H.SW mice, with 5.1/5.2 and 8.1/8.2 being the most prominent in both the groups. The Vb profiles of the populations responding to the peptide mHAg's were different. In the anti-H13 culture a single family, Vb3, dominated the response. In the anti-H3 culture the single prominent family was Vb7. In contrast, several Vb families were prominent in the antiB6dom1 culture; Vb10b, 8.3 and 6 each comprised X15% of the CD8+ cells and Vb9 showed a substantial increase compared to naive and whole cell stimulated immune cells.
Hematopoietic stem cell donor immunity to the immunodominant mHAg B6dom1 is neither sufficient nor necessary for the induction of severe GVHD Since the greatest portion of the cytolytic immune response in SW anti-B6 immune responses appears to be directed at the immunodominant antigen B6dom1, we hypothesized that an anti-B6dom1 response would be sufficient for the induction of severe GVHD in B6 recipients. Given the relatively modest allogeneic responses to H3 and H13, we further hypothesized that responses directed solely at either H3 or H13 would not be sufficient for the induction of severe GVHD. To test these hypotheses, spleen cells from SW donors immunized against B6dom1-, H3-or H13 peptide epitopes were adoptively transferred into lethally irradiated B6 recipients. Animals transplanted with naive SW or irrelevant peptide (NP)-immune spleen cells served as negative controls. Recipients transplanted with alloimmunized donor spleen cells served as positive controls for GVHD. Figure 8a demonstrates that at the time of transplant, the various donor groups had specific immune activity against the particular mHAg. Recipients were monitored for GVHD. Figure 8b describes the weights of the groups. All the animals in GVHD control groups displayed severe GVHD and had to be killed by day 35 because of severe morbidity (severe weight loss, hunched posture, dermatitis). In contrast, no recipients of cells specifically immune to the B6dom1 or H13 exhibited severe GVHD; that is, did not exhibit significant weight loss, hunched posture or dermatitis. Similarly four of five recipients of H3 immune cells had no evidence of GVHD; a single recipient exhibited dermatitis.
Histological examination of the liver for GVHD was also performed in some transplant recipients. In the positive GVHD control group that received cells from C57BL/6 cell-primed donors, three of three animals had substantial mononuclear infiltrates in the regions of the portal triads, classic for hepatic GVHD. Two of five recipients of B6dom1-immune cells showed similar hepatic infiltrates despite having no outward signs of GVHD. Similarly, only one of five recipients of either H3 or H13 immune cells had GVHD-infiltrates in the liver; these animals also had no outward signs of GVHD.
While donor T-cell reactivity toward B6dom1 alone was insufficient to induce severe GVHD, we hypothesized that such anti-B6dom1 reactivity may be necessary for severe GVHD. To test this hypothesis, we attempted to blunt the response of C3H.SW donors to B6dom1 by a series of i.v. infusions of B6dom1 peptide prior to alloimmunization with whole irradiated recipient-strain C57BL/6 tumor cells. These donors were then used to transplant C57BL/6 mice which were then observed over 8 weeks for GVHD. mice. Despite the absence of an anti-B6dom1 response, recipients demonstrated severe GVHD with weight loss and mortality indistinguishable from the group receiving grafts from alloimmunized donors (Figures 9b and c) .
Discussion
These experiments defined the immunodominance relations of molecularly characterized mHAgs in the MHC-matched allogeneic C3H.SW4C57BL/6 transplant model. B6dom1, a product of the H7 locus, dominated the allogeneic response. Responses to H3 and H13 were substantially smaller, although the dominance of B6dom1 over H3 and H13 was not as complete as its dominance of the HY antigen. B6dom1 immunodominance was observed even when the mHAgs were presented on separate antigenpresenting cells. The relative magnitude of the B6dom1 response was greater after three immunizations than after one, suggesting that either a larger number of T-cell clones in the donor repertoire respond to B6dom1, or that such clones undergo a more efficient clonal expansion. B6dom1 elicited a broader variety of Vb clonotypes than either H3 or H13.
The mechanism of the immunodominance of B6dom1 is not yet known. However, these studies show that the immunodominance is not because of intrinisic differences in peptide-MHC avidity or affinity as measured by external loading of class I MHC molecules. An alternative potential mechanism related to the antigen per se is minor antigen density on C57BL/6 cells. Other studies of the minor antigens indicate that B6dom1 is present at greater than 1000 peptide-class I complexes per cell, 3 while the densities of H3 and H13 have been estimated at 50-100 per cell. 5 A recent report comparing the immunodominance of B6dom1 and HY attributed a significant portion of the effect to the fact that HY is present at approximately 10 copies per cell, roughly 2 logs less than B6dom1. This was associated with a more rapid expansion of the T-cell populations responding to B6dom1. This potentially results in a situation in which a larger population of anti-immunodominant antigen T cells colonizes surface area on APCs that express higher immunodominant antigen density, effectively monopolizing physical space on the APC and blunting activation or expansion of T cells reactive with the subdominant HY antigen. 8 The observation in the current report that immunodominance of B6dom1 over H3 and H13 was greater after multiple exposures to alloantigens is compatible with such a model. Such a physical competition for APC surface area is also compatible with our observation that anti-H3 and anti-H13 responses could be elicited more efficiently by APCs externally loaded with antigen compared to C57BL/6 APCs that endogenously express all the three antigens. However, physical competition for APCs is not a complete explanation, since the magnitude of antiB6dom1 responses was consistently greater even when separate APCs presented the mHAgs. One explanation for higher antigen density would be that the precursor protein for the B6dom1 peptide may be substantially more abundant in the cell than the proteins from which H3 and H13 are derived. An alternate hypothesis is that the B6dom1 precursor protein is not more abundant, but is more efficiently degraded and transported into the endoplasmic reticulum where class I MHC synthesis occurs, a phenomenon observed in studies of the intracellular pathogen, Listeria monocytogenes. 21 Our observations that H3 and H13 appear to stabilize D b more efficiently than B6dom1 do not support another alternate hypothesis that the immunodominant peptide is present at similar concentrations in the endoplasmic reticulum but more efficiently competes for incorporation into class I complexes. Direct testing of these hypotheses is not feasible at this time, since monoclonal antibodies to the proteins giving rise to B6dom1, H3 and H13 are not available.
An additional mechanism of immunodominance of mHAgs has been suggested in a recent report describing the hierarchy of mHAgs in the C57BL/6 female 4 BALB.B male transplant model. In this model, the H60 minor antigen dominates a number of other minor antigens including HY and H13. 22 Here the repertoire of anti-H60 T cells was substantially more diverse than those responding to less dominant antigens. This greater diversity was attributed to the fact that in the donor strain an allelic variant of H60 is not expressed in contrast with the H13 antigen in which an allelic variant is expressed. The presence of a self-analog for the subdominant antigens may lead to intrathymic loss of T-cell clones, while the absence of a self-analog for the immunodominant antigen allows a greater diversity of reactive T cells clones to survive thymic negative selection. Our observation that B6dom1 elicits responses from a broader variety of Vb clonotypes is consistent with such a mechanism in this transplant model.
The current studies also assessed the relative contributions of donor T cells specific for B6dom1, H3 and H13 to the initiation of GVHD. We observed that immunity directed against only B6dom1, H3 or H13 was insufficient to induce severe, systemic GVHD. This is consistent with the recent report from Fontaine et al 11 that indicated that infusion of donor T cells specific for B6dom1 did not induce GVHD, but nonetheless resulted in a significant GVT effect. Our results differed slightly in that modest hepatic GVHD was present in some recipients of peptidespecific donor cells, while in the other report there was no evidence of hepatic involvement as assessed by hepatic enzyme measurements. This difference might be explained by the fact that in the current experiments spleen cells from peptide primed animals were infused, while in the other study relatively pure, in vitro expanded T-cell populations were infused. It is conceivable that the activity of the peptide-primed cells was sufficient to provide conditions suitable for the activation of potentially alloreactive naive T cells in the splenic population directed against other epitopes. This is similar to the finding of Fontaine et al, that the use of unfractionated spleen cells from C3H.SW donors primed with B6dom1 peptide did induce GVHD in some B10 recipients. 11 The current study also demonstrated that pretreatment of donors to blunt the response to the immunodominant B6dom1 prior to exposure to allogeneic C57BL/6 cells that express the entire ensemble of mHAgs did not prevent fatal GVHD, indicating that a robust anti-B6dom1 CD8 Blunting of the donor response to the immunodominant antigen, B6dom1, does not prevent severe graft versus host disease. SW mice were immunized i.p. a total of two times weekly with 5 Â 10 6 pulsed spleen cells. A cohort of donors was tolerized to B6dom1 prior to the initiation of immunization by four intravenous injection of 300 mg of B6dom1 peptide every 3 days. The day before each immunization episode, the B6dom1-pretreated group received one additional intravenous injection of 300 mg of B6dom1. At 2 weeks after the last immunization, donors were killed and spleen cells were (a) stimulated for 5 days in vitro with B6dom1, H3 or H13 peptide-loaded naive SW splenocytes. Following stimulation, the effectors were tested for cytolytic activity EL-4 target cells. Naive SW cells stimulated with each peptide were used as negative controls (averaged lysis of the all peptides combined and the lysis of target cells in the each group was o10%). Lethally irradiated C57BL/6 mice were infused with 4 Â 10 6 bone marrow and 10 Â 10 6 spleen cells from either B6dom1-tolerized (n ¼ 9) or nontolerized 205 fibrosarcoma-immune donors (n ¼ 5) and monitored for GVHD by weight loss (b) and overall survival (c). The naive SW4B6 transplantation served as negative control for GVHD. response was not necessary for severe GVHD. One interpretation of this observation is that severe, systemic GVHD is the consequence of activation of multiple T-cell populations against multiple mHAg and that loss of reactivity against one (even the most immunodominant) does not prevent GVHD. This conclusion is consistent with the failure to observe severe GVHD using single mHAgprimed donors. In other models, it has been observed that adoptive transfer of only CD8 cells specific for a single mHAg does not produce severe GVHD. 11, 23 An alternate interpretation is that donors pretreated with B6dom1 peptide may not generate significant CD8 effectors against the immunodominant epitope, but nonetheless may be generating CD4 responses against putative class II-associated antigens derived from the H7 gene product. While CD8 responses have been shown to be critical for severe GVHD in this model, 2 in many immune responses CD4 responses significantly contribute to the magnitude and durability of CD8 responses. 24 This points to the major limitation of this study in defining the immunodominance hierarchy of mHAgs in this model: the lack of knowledge of the allogeneic epitopes to which donor CD4 cells respond. The techniques used to identify mHAgs, while technically difficult, have primarily identified CD8, class I-restricted epitopes. However, recent reports have identified class II-restricted epitopes in other systems using dendritic cells to process appropriately and present class II antigens derived from transient expression in neighboring cells in vitro. 25 Based on such technical progress, it may be possible in the future to identify more fully the important CD4 and CD8 epitopes in transplant settings, which might allow therapeutic manipulation of the complex alloreactive responses that underlie GVHD and GVT effects. Studies in humans will be more complex than in murine models owing to the greater complexity of minor antigens in the outbred human population and the multiple immune mechanisms that contribute to GVHD. Nonetheless, a greater understanding of immunodominance among mHAgs may contribute to improved outcomes in transplantation.
